Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, Dazublys, indicated for HER2-positive cancers. This marks CuraTeQ’s third EMA-approved biosimilar in 2025, reinforcing Aurobindo’s focus on biosimilars with plans for 10 launches by 2030. Analysts predict a potential 20% upside for Aurobindo Pharma shares, with a consensus ‘Buy’ rating.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets